Sei Investments Co. Raises Stake in Oruka Therapeutics, Inc. $ORKA

Sei Investments Co. increased its holdings in shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA) by 136.0% during the 1st quarter, HoldingsChannel reports. The fund owned 22,840 shares of the company’s stock after buying an additional 13,164 shares during the period. Sei Investments Co.’s holdings in Oruka Therapeutics were worth $1,120,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Viking Global Investors LP purchased a new stake in shares of Oruka Therapeutics in the 3rd quarter worth approximately $51,280,000. Paradigm Biocapital Advisors LP purchased a new position in Oruka Therapeutics during the fourth quarter valued at $51,840,000. Remedium Capital Partners LLC bought a new stake in Oruka Therapeutics in the fourth quarter worth $47,054,000. Deep Track Capital LP grew its stake in shares of Oruka Therapeutics by 38.4% in the third quarter. Deep Track Capital LP now owns 2,654,781 shares of the company’s stock worth $51,051,000 after acquiring an additional 735,983 shares during the last quarter. Finally, State Street Corp grew its position in Oruka Therapeutics by 112.2% during the 4th quarter. State Street Corp now owns 1,383,847 shares of the company’s stock valued at $41,944,000 after purchasing an additional 731,819 shares during the last quarter. Hedge funds and other institutional investors own 56.44% of the company’s stock.

Insider Buying and Selling

In other Oruka Therapeutics news, SVP Arjun Agarwal sold 10,290 shares of Oruka Therapeutics stock in a transaction that occurred on Monday, May 18th. The shares were sold at an average price of $59.07, for a total transaction of $607,830.30. Following the transaction, the senior vice president owned 16,406 shares of the company’s stock, valued at $969,102.42. The trade was a 38.55% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Carl Dambkowski sold 105,000 shares of the stock in a transaction on Thursday, May 21st. The stock was sold at an average price of $58.97, for a total transaction of $6,191,850.00. Following the completion of the sale, the director directly owned 73,743 shares of the company’s stock, valued at approximately $4,348,624.71. This trade represents a 58.74% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 188,406 shares of company stock valued at $12,019,683 in the last 90 days. Corporate insiders own 23.49% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on the stock. Barclays increased their price target on shares of Oruka Therapeutics from $78.00 to $160.00 and gave the company an “overweight” rating in a report on Monday, April 27th. Wedbush reissued an “outperform” rating and issued a $165.00 target price on shares of Oruka Therapeutics in a report on Tuesday. Piper Sandler restated an “overweight” rating and set a $180.00 target price on shares of Oruka Therapeutics in a research note on Tuesday, June 2nd. BTIG Research reiterated a “buy” rating and issued a $151.00 price target on shares of Oruka Therapeutics in a research note on Tuesday. Finally, HC Wainwright restated a “buy” rating and set a $120.00 price objective on shares of Oruka Therapeutics in a research report on Monday, August 3rd. Ten research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $134.30.

Oruka Therapeutics Stock Up 2.6%

Shares of NASDAQ:ORKA opened at $107.40 on Thursday. The stock has a market capitalization of $7.11 billion, a PE ratio of -52.91 and a beta of -0.34. The firm’s 50 day moving average price is $85.59 and its 200-day moving average price is $61.75. Oruka Therapeutics, Inc. has a twelve month low of $14.03 and a twelve month high of $109.42.

Oruka Therapeutics (NASDAQ:ORKA) last released its quarterly earnings results on Monday, August 10th. The company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.04). Analysts expect that Oruka Therapeutics, Inc. will post -2.25 earnings per share for the current fiscal year.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.